This simple, dietitian-designed week of meals ensures you’re getting all your essential nutrients while on a GLP-1 weight ...

Injectables for type 2 diabetes and weight loss could soon be a thing of the past. Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule ...

The traditional diet of restricting calories is a tried-and-true method for weight loss — but new research reveals that a certain intermittent fasting regimen may be more effective. Researchers ...

1 Phase 1 trials plan to assess ALX2004 in solid tumors that express EGFR mutations and will begin mid-2025. Initial safety data are expected to be available in the first half of 2026. “Clinical ...

Here is a quick look at what the Senate plan would accomplish, and what to expect in the days ahead as lawmakers move to the next phase. An extension for ... The bill also provides for an additional ...

Americans have struggled to afford the blockbuster class of weight loss medications called GLP-1, or glucagon-like peptide-1, receptor agonists. The drugs were first used to treat diabetes but ...

"The Masked Singer" judge Jenny McCarthy recently said she "almost died" after trying a vegan diet. The 52-year-old actress, television personality and wife of actor Donnie Wahlberg shared on the ...

What does this mean for India’s weight-loss industry? As per recent data from the National Family Health Survey (NFHS-5), nearly 24% of women and 22.9% of men in India are overweight or obese. With ...

Related Massive study looks at benefits, risks of GLP-1 weight-loss drugs GLP-1 medications show promise in slowing kidney disease progression Cosmetic surgeons try to correct 'Ozempic face' for ...

GLP-1 Drug Use For Weight Loss Has Soared, Costing Billions By Dennis Thompson HealthDay Reporter TUESDAY, April 1, 2025 (HealthDay News) -- The number of Americans taking cutting-edge weight-loss ...

The number of Americans taking cutting-edge weight-loss drugs like Ozempic ... The number of people without diabetes taking a GLP-1 drug more than tripled between 2018 and 2022 in the U.S ...